# EDGAR Filing Document

**Accession Number:** 0001224962
**File Stem:** 0001193125-25-331145
**Filing Date:** 2025-12
**Character Count:** 16238
**Document Hash:** 956ee576c21baebc7f072f81b36a6bd2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-331145.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001193125-25-331145

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Athira Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001620463
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 453368487
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91705
- **FILM NUMBER:** 251601725

**BUSINESS ADDRESS:**
- **STREET 1:** 18706 NORTH CREEK PARKWAY, SUITE 104
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98011
- **BUSINESS PHONE:** (425) 620-8501

**MAIL ADDRESS:**
- **STREET 1:** 18706 NORTH CREEK PARKWAY, SUITE 104
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** M3 Biotechnology, Inc.
- **DATE OF NAME CHANGE:** 20140924
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PERCEPTIVE ADVISORS LLC
- **CENTRAL INDEX KEY:** 0001224962

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 51 ASTOR PLACE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003
- **BUSINESS PHONE:** 646-205-5300

**MAIL ADDRESS:**
- **STREET 1:** 51 ASTOR PLACE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003

## Exhibit 7.1

**EXHIBIT 7**

AGREEMENT

The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: December 23, 2025

PERCEPTIVE ADVISORS LLC

By: <u>/s/ Joseph Edelman</u>

Name: Joseph Edelman

Title: Managing Member

<u>/s/ Joseph Edelman</u>

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: <u>/s/ Joseph Edelman</u>

Name: Joseph Edelman

Title: Managing Member

PERCEPTIVE XONTOGENY VENTURE FUND II, L.P.

By: Perceptive Xontogeny Venture II GP, LLC, its general partner

By: <u>/s/ Joseph Edelman</u>

Name: Joseph Edelman

Title: Managing Member

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**Athira Pharma, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value**

*(Title of Class of Securities)*

**04746L203**

*(CUSIP Number)*

**Alexander Rakitin**<br>Perceptive Advisors LLC, 51 Astor Place<br>10th Floor<br>New York NY 10003<br>(646) 205-5345

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/23/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **04746L203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Perceptive Advisors LLC** | Name of reporting person<br>**Perceptive Advisors LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1859322.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1859322.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1859322.00** | Aggregate amount beneficially owned by each reporting person<br>**1859322.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

| **CUSIP No.** | **04746L203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Joseph Edelman** | Name of reporting person<br>**Joseph Edelman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1869050.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1869050.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1869050.00** | Aggregate amount beneficially owned by each reporting person<br>**1869050.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**20.1%** | Percent of class represented by amount in Row (11)<br>**20.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **04746L203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Perceptive Life Sciences Master Fund, Ltd.** | Name of reporting person<br>**Perceptive Life Sciences Master Fund, Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1529566.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1529566.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1529566.00** | Aggregate amount beneficially owned by each reporting person<br>**1529566.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**16.4%** | Percent of class represented by amount in Row (11)<br>**16.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **04746L203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Perceptive Xontogeny Venture Fund II, LP** | Name of reporting person<br>**Perceptive Xontogeny Venture Fund II, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**329756.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**329756.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**329756.00** | Aggregate amount beneficially owned by each reporting person<br>**329756.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.5%** | Percent of class represented by amount in Row (11)<br>**3.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value

**(b) Name of Issuer:**
Athira Pharma, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
18706 North Creek Parkway, Suite 104, Bothell, WA, 98011

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is amended and supplemented as follows:

The information set forth in Item 6 of this Amendment No. 5 is incorporated by reference to this Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 of the Schedule 13D is amended and supplemented as follows:

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on an aggregate of 9,300,434 shares of Common Stock outstanding, consisting of (i) 3,943,887 shares of Common Stock outstanding as of November 5, 2025, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 6, 2025, and (ii) 5,356,547 shares of Common Stock issued in the Private Placement.

**(b)**
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Mr. Edelman's cover page includes 9,728 shares of Common Stock that may be acquired upon the exercise of vested options awarded to Mr. Edelman in connection with his role as a director of the Issuer. As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants.

**(c)**
On December 18, 2025, the Master Fund and PXV II acquired 989,270 shares and 329,756 shares of Common Stock, respectively, at a purchase price of $6.35 per share, 1,372,935 and 457,645 Pre-Funded Warrants, respectively, at a purchase price of $6.349 per share, 3,838,583 and 1,279,526 Series A Warrants and 3,543,307 and 1,181,101 Series B Warrants, respectively, pursuant to the transactions contemplated by the Securities Purchase Agreement. Except for the transactions described in this Item 5(c), none of the Reporting Persons has effected any transaction in shares of Common Stock since the filing of Amendment No. 4 to the Schedule 13D, filed with the Securities and Exchange Commission on December 22, 2025.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is amended and supplemented as follows:

In connection with the closing of the transactions contemplated by the Securities Purchase Agreement, on December 23, 2025, the Master Fund and PXV II entered into a registration rights agreement (the "Registration Rights Agreement") with the Issuer pursuant to which the Issuer agreed to prepare and file a registration statement to register the resale of the shares of Common Stock and shares underlying Warrants purchased pursuant to the Securities Purchase Agreement within thirty calendar days after the date of the Closing and to use reasonable best efforts to have the registration statement declared effective at the earliest possible date but no later than the earlier of (a) seventy-five calendar days after the filing date if the SEC notifies the Issuer that it will review the registration statement and (b) the fifth business day after the Issuer is notified by the SEC that the registration statement will not be reviewed or will not be subject to further review. If the Issuer fails to meet certain of the requirements in the Registration Rights Agreement following the Closing, the Issuer will pay liquidated damages to the Master Fund and PXV II as provided in the PIPE Registration Rights Agreement.

The foregoing description of the Registration Rights AGreement is qualified in its entirety by reference to the full text of the agreement, a copy of which is included as Exhibit 8 hereto.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Perceptive Advisors LLC

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman, Managing Member

**Date:** 12/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Joseph Edelman

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman

**Date:** 12/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Perceptive Life Sciences Master Fund, Ltd.

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman, Managing Member

**Date:** 12/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Perceptive Xontogeny Venture Fund II, LP

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman, Managing Partner

**Date:** 12/23/2025